TransCon CNP

Designed for continuous CNP exposure to rebalance bone growth in skeletal disorders

Designed for continuous CNP exposure to rebalance bone growth in skeletal disorders

Vector-Smart-Object-copy

TransCon technology has extended exposure of CNP from 2.5 minutes to 120 hours - unlocking its therapeutic potential to pursue a new frontier of growth biology.

Explore

You are about to access www.ascendispharma.com. Click below if you wish to proceed.